ELEVATING TOMORROW’S STANDARD OF CANCER CARE TODAY
WELCOME TO ABALYTICS ONCOLOGY
10 million people die from cancer every year. It remains the cause of every sixth death. At Abalytics Oncology, our vision is to redefine the standard of cancer care in the 21st century.
Core Values
How do you approach cancer treatment in the age of artificial intelligence? Where do you choose to focus? At Abalytics Oncology, three simple values drive every action we take.
Overall survival
Quality of life
Greater Understanding
Strategic Missions for 2025 and Beyond
01
Bring best-in-class anti-CTLA4 to patients in 2025
02
Develop targeted next-generation antibody-based therapies
03
Build Data Model, Pipeline, And System Integrations to Solve Cancer Immune Resistance
Abalytics Stands for Antibody Data Analytics
Abalytics Intelligence
Sequences
Clinical Trials
Structures
Publications
Patents
Biomarkers
Companies
Technologies
Investments
Code
Real-world information, in real-time
Artificial Intelligence generates infinite options, which human intelligence evolved to constrain.
Abalytics Algorithms
Target selection
Antibody design
Lead identification
Translational modeling
Treatment optimization
Resource allocation
Abalytics Therapies
Immune Checkpoint Inhibitors
Antibody Drug Conjugates
Targeted Therapies
We use computational antibody design and biomolecular engineering to develop better treatments
Pipeline
ABAO2 primes the immune system for the new age of targeted combination therapies
Program
Discovery
IND-Enabling Studies
Status
Best-in-Class Immune Checkpoint Inhibitor with Improved Safety and Efficacy
ABAO2
Anti-CTLA4
Ready for Phase 1
Next generation antibody-based pMHC targeted therapies
ABAO3
mKRAS
R&D
ABAO4
PRAME
R&D
ABAO5
MAGE-A4
R&D
NY-ESO-1
R&D
ABAO2 combines features validated to improve safety and efficacy to deliver the best-in-class anti-CTLA4
Features
Opportunity
Validated epitope
Minimize Uncertainty
PH-Dependent Binding
Minimize Toxicity
Next-gen Fc
Maximize Efficacy
- Ipilimumab and Tremelimumab validate anti-CTLA4 development in solid tumors
- Robust Overall Survival across tumor types limited by the severe immune related Adverse Events (irAE) of legacy approaches
- Novel insights demonstrate the feasibility of delivering anti-CTLA4 efficacy without the toxicity
Abalytics Oncology next generation antibody-based pMHC targeted therapies aim to distinguish cancer from self
The information age has unveiled new strategies for priming the immune system against neoantigens, which are encoded signals displayed on the surface of cancer cells
The Abalytics computational antibody design system improves on existing TCR and TCR mimetic drug discovery approaches
Modular next-generation antibody-based formats offer validated options to optimize
safety, efficacy, and developability
Abalytics Oncology Therapies target the black box that is cancer immune resistance
Abalytics Oncology Therapies
Immune Checkpoint Inhibitors
Antibody Drug Conjugates
Targeted Therapies
Cancer Immune Resistance
Suppression
Blockage and downregulation of immune response
Exhaustion
Body loses key line of
defense
Evasion
Tumor cells are invisible to the
immune system
SUCCESS OUTCOMES
Tumor shrinkage
Durable responses
Overall survival
Our Founders
Akshay Paintal
CEO
Shay combines a track record of computational antibody design and development with a decade of experience implementing data analytics systems across diverse healthcare settings. He is credited with the invention of Omoprubart and has executed on over 15 other cutting edge drug development programs, including TY027. Before formalizing a system for computational antibody design in the Sasisekharan Lab at MIT’s Koch Institute for Integrative Cancer Research, Shay developed technology solutions for public and private sector clients exploring practical applications of artificial intelligence.
Manish Potti
Chief Business Officer
Manish has a track record of execution in the biopharmaceutical industry. He was the Chief Business Officer of Shinkei Therapeutics, a CNS focused company. He was previously the President and co-founder of Innogenix Pharmaceuticals. At Innogenix, Manish took a brownfield project through FDA facility approval, directed the R&D strategy, in-licensed assets, and grew the revenue to a stable base. He was also the head of business development of Epic Pharma, where he led the sale process of the company to Humanwell Healthcare of China in 2016. Since 2016, he has been actively investing and managing portfolio companies in health care
Contact us
Connect with us about reshaping the future of cancer care today.
